Cita APA

Kantarjian, H. M., Martinelli, G., Jabbour, E. J., Quintás-Cardama, A., Ando, K., Bay, J., . . . Giagounidis, A. (2013). Stage I of Phase II study assessing efficacy, safety and tolerability of barasertib (AZD1152) versus LDAC in elderly AML patients.

Citación estilo Chicago

Kantarjian, Hagop M., et al. Stage I of Phase II Study Assessing Efficacy, Safety and Tolerability of Barasertib (AZD1152) Versus LDAC in Elderly AML Patients. 2013.

Cita MLA

Kantarjian, Hagop M., et al. Stage I of Phase II Study Assessing Efficacy, Safety and Tolerability of Barasertib (AZD1152) Versus LDAC in Elderly AML Patients. 2013.